Antipsychotics - For a Healthy Belgium

Key figures
Data
Graphics
Comments

PRESCRIBERS
Main prescribers: General practitioners	60.90%
RATE OF USE
Annual consumption (DDD)	55,761,591
Standardised rate of use (per 100,000 insured persons)	486,356.17
Average annual consumption per patient (DDD)	149.35
% Insured persons concerned	3.26%
Approximate % DDD issued outside the insurance	10.39%
% Patients with more than 3 times the average consumption	8.22%
POPULATION
Median age	52 years
Max/min ratio of the median age (by district)	1.10
Percentage of women	46.60%
Ratio Preferential scheme/General scheme	8.51
CONSUMPTION TRENDS (DDD)
Trend 2011-2021	1.09%
Trend 2011-2019	0.40%
Trend 2019-2021	3.92%
GEOGRAPHICAL VARIATIONS
Coefficient of variation 2011-2013	14.87
Coefficient of variation 2019-2021	15.36
Max/min ratio of consumption (DDD per 100,000 insured persons, by region)	1.16
Max/min ratio of consumption ( DDD per 100,000 insured persons, by district)	1.88
DIRECT EXPENDITURE
Annual expenditure charged to the insurance	81,198,233€
Average annual expenditure per insured person	7.08 €
Average patient share (under insurance)	11.56%
Max/min ratio of expenditure per insured person (by region)	1.27
Max/min ratio of expenditure per insured person (by disctrict)	2.29
% “Low-cost” medication	70.59%

On this table, when a statistical test has been performed, the data showing a significant difference is displayed on an yellow background, otherwise on a grey background.

+ - ATC codes selected for analysis Click to collapse

CODES	LABEL	LABEL ATC-5
N05AA02	LEVOMEPROMAZINE	PHENOTHIAZINES SUBSTITUEES AVEC UNE CHAINE ALIPHATIQUE
N05AD01	HALOPERIDOL	DERIVES DE LA BUTYROPHENONE
N05AD05	PIPAMPERONE	DERIVES DE LA BUTYROPHENONE
N05AD06	BROMPERIDOL	DERIVES DE LA BUTYROPHENONE
N05AE03	SERTINDOLE	DERIVES INDOLIQUES
N05AF01	FLUPENTIXOL	DERIVES DU THIOXANTHENE
N05AF05	ZUCLOPENTHIXOL	DERIVES DU THIOXANTHENE
N05AG01	FLUSPIRILENE	DERIVES DE LA DIPHENYLBUTYLPIPERIDINE
N05AG02	PIMOZIDE	DERIVES DE LA DIPHENYLBUTYLPIPERIDINE
N05AH02	CLOZAPINE	DIAZEPINES, OXAZEPINES, THIAZEPINES ET OXEPINES
N05AH03	OLANZAPINE	DIAZEPINES, OXAZEPINES, THIAZEPINES ET OXEPINES
N05AH04	QUETIAPINE	DIAZEPINES, OXAZEPINES, THIAZEPINES ET OXEPINES
N05AH05	ASENAPINE	DIAZEPINES, OXAZEPINES, THIAZEPINES ET OXEPINES
N05AH06	CLOTIAPINE	DIAZEPINES, OXAZEPINES, THIAZEPINES ET OXEPINES
N05AL01	SULPIRIDE	BENZAMIDES
N05AL03	TIAPRIDE	BENZAMIDES
N05AL05	AMISULPRIDE	BENZAMIDES
N05AN01	SELS DE LITHIUM	SELS DE LITHIUM
N05AX07	PROTHIPENDYL	AUTRES ANTIPSYCHOTIQUES (NEUROLEPTIQUES)
N05AX08	RISPERIDONE	AUTRES ANTIPSYCHOTIQUES (NEUROLEPTIQUES)
N05AX12	ARIPIPRAZOLE	AUTRES ANTIPSYCHOTIQUES (NEUROLEPTIQUES)
N05AX13	PALIPERIDONE	AUTRES ANTIPSYCHOTIQUES (NEUROLEPTIQUES)

The labels on a blue background are the medicines that exist under the status "low cost".
The codes mentioned above can be used in rates and expenses, or only in expenses. We invite you to consult the full report for more information.

Click here to see the graph illustrating the evolution of the breakdown by volume of ATC codes used for the rates.